MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma

This study is testing a CAR-T cell therapy approach guided by MRD (minimal residual disease) monitoring for multiple myeloma patients who cannot undergo a stem cell transplant. MRD measures tiny amounts of leftover cancer — the idea is to tailor immunotherapy based on how much disease remains. **You may be eligible if:** - You are between 18 and 75 years old - You have newly diagnosed multiple myeloma - You are NOT eligible for a stem cell transplant (for example, due to age 65+, poor performance status, or failed stem cell collection) - Your cancer cells test positive for BCMA and GPRC5D - Your liver and kidney function are adequate **You may NOT be eligible if:** - You are eligible for a stem cell transplant and willing to undergo one - Your cancer does not express BCMA or GPRC5D - Your organ function does not meet the study's requirements Talk to your doctor to see if this trial is right for you.